GeneDx Secures New $100 Million Term Loan Facility
TipRanks (Mon, 2-Mar 7:47 AM ET)
PRNewswire (Wed, 25-Feb 8:03 PM ET)
GeneDx to Participate in Upcoming Investor Conferences
Business Wire (Wed, 25-Feb 8:30 AM ET)
GeneDx Achieves Record Growth in 2025, Drives Genomic Expansion and Reaffirms 2026 Outlook
Market Chameleon (Mon, 23-Feb 2:50 AM ET)
Business Wire (Mon, 23-Feb 6:30 AM ET)
Business Wire (Wed, 11-Feb 9:05 AM ET)
GeneDx to Report Fourth Quarter 2025 Financial Results on Monday, February 23, 2026
Business Wire (Tue, 3-Feb 8:00 AM ET)
Business Wire (Thu, 15-Jan 11:24 AM ET)
Market Chameleon (Mon, 12-Jan 3:17 AM ET)
GeneDx Announces Preliminary 2025 Financial Results and Provides 2026 Guidance
Business Wire (Mon, 12-Jan 7:30 AM ET)
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.
Genedx Holdings Corp. - Class A trades on the NASDAQ stock market under the symbol WGS.
As of March 5, 2026, WGS stock price climbed to $82.00 with 789,610 million shares trading.
WGS has a beta of 1.28, meaning it tends to be more sensitive to market movements. WGS has a correlation of 0.06 to the broad based SPY ETF.
WGS has a market cap of $2.37 billion. This is considered a Mid Cap stock.
Last quarter Genedx Holdings Corp. - Class A reported $121 million in Revenue and $.14 earnings per share. This beat revenue expectation by $1 million and exceeded earnings estimates by $.02.
In the last 3 years, WGS traded as high as $170.87 and as low as $1.16.
The top ETF exchange traded funds that WGS belongs to (by Net Assets): ARKK, VTI, IWM, ARKG, VXF.
WGS has underperformed the market in the last year with a price return of -17.2% while the SPY ETF gained +19.4%. WGS has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -49.4% and -10.9%, respectively, while the SPY returned -0.2% and -0.7%, respectively.
WGS support price is $75.75 and resistance is $83.19 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that WGS shares will trade within this expected range on the day.